The Discovery
The Mealtime Problem
The Blood Sugar Spike Nobody Could Tame
Key moment
Post-meal blood sugar spikes linked to heart damage and complications
By the early 2000s, diabetes doctors had a frustrating gap in their toolbox. They could manage fasting blood sugar fairly well — that's the number you get in the morning before eating. But the blood sugar spikes that hit after every meal were much harder to control.
These post-meal spikes were dangerous. Research showed they damaged blood vessels, increased heart risk, and contributed to the complications that make diabetes so devastating. Insulin could blunt the spikes, but timing the dose was tricky. Too much insulin before a meal meant a dangerous crash a few hours later. Too little meant the spike went unchecked.
Doctors needed something that could target mealtimes specifically — a drug that would work fast when food arrived, then quiet down when it wasn't needed.
The Breakthrough
The Six-Lysine Trick
Redesigning a Lizard Hormone in Copenhagen
Key moment
Six extra lysine amino acids gave the drug its unique mealtime power
At Zealand Pharma in Copenhagen, Denmark, peptide chemists were studying exendin-4 — the Gila monster hormone that had already become the drug exenatide (Byetta). They wanted to create a better version.
Their approach was elegant. They took the 39-amino-acid exendin-4 sequence and made two changes: they removed one amino acid (proline) from position 38 and added six lysine residues to the tail end. These extra lysines — positively charged amino acids — made the peptide more stable and gave it a unique action profile.
The result was lixisenatide, a 44-amino-acid peptide that was especially potent at slowing stomach emptying. This meant it was exceptionally good at controlling post-meal blood sugar spikes — better than some drugs that were more powerful overall. Zealand had found a niche.
In 2003, French pharmaceutical giant Sanofi licensed lixisenatide for global development. They saw something others missed: a drug that was best at the specific problem doctors needed solved most.
The Trials
The GetGoal Trials
Proving Its Worth Across the Globe
Key moment
Approved in Europe in 2013 but delayed for years in the US
Sanofi launched a massive clinical trial program called GetGoal — a series of studies testing lixisenatide in different patient populations around the world. Across the program, the drug consistently showed strong control of post-meal blood sugar spikes and meaningful weight loss.
In February 2013, the European Medicines Agency approved lixisenatide as Lyxumia. But in the United States, things got complicated. The FDA wanted to see the results of a large cardiovascular safety trial — ELIXA — before granting approval. This was the post-Vioxx era, and regulators were taking no chances with drugs used by millions.
Sanofi had to wait. While competitors like liraglutide and dulaglutide raced ahead in the US market, lixisenatide sat on the sidelines, trapped in regulatory limbo.
The Crisis
The Late Arrival
Coming to America Three Years Behind
Key moment
FDA approval came 3 years after Europe — competitors had pulled ahead
The ELIXA trial results came in 2015: lixisenatide was heart-safe. It didn't increase cardiovascular events — but it didn't reduce them either, unlike liraglutide's LEADER trial. In a market now obsessed with GLP-1 drugs that protected the heart, this was a disappointment.
The FDA approved Adlyxin on July 28, 2016 — more than three years after Europe. By then, Victoza (liraglutide) dominated the market, and Trulicity (dulaglutide) was gaining fast. Lixisenatide had missed its window as a solo drug.
But Sanofi had a backup plan. They had been quietly developing something that would give lixisenatide a second life: a combination product that mixed it with the world's most popular insulin.
The Legacy
The Perfect Partner
Finding New Life in Combination
Key moment
Soliqua: first-ever GLP-1 + insulin combination in a single pen
In November 2016, the FDA approved Soliqua — a single injection combining lixisenatide with insulin glargine (Lantus). It was the first fixed-dose combination of a GLP-1 drug and a long-acting insulin.
The combination was brilliant in its simplicity. Insulin glargine controlled fasting blood sugar throughout the day and night. Lixisenatide, with its strong mealtime action, tamed the post-meal spikes. Together, they covered both problems in one daily shot — and the GLP-1 component helped offset the weight gain that insulin typically causes.
For patients who needed both insulin and a GLP-1 drug, Soliqua meant one injection instead of two. One pen instead of two. One copay instead of two. It was the kind of practical, patient-friendly solution that doesn't make headlines but changes daily lives.
Lixisenatide may not have become the blockbuster that Victoza or Trulicity did. But as one half of a powerful combination drug, it found exactly where it belonged — not as the star of the show, but as the perfect supporting player.
Peptide history · 2003
Lixisenatide (Adlyxin / Lyxumia)
The Mealtime Guardian Built From Lizard DNA
Born from the same Gila monster venom as exenatide but redesigned with a tail of six extra amino acids, lixisenatide found its calling not as a blood sugar workhorse, but as a mealtime specialist — and eventually as half of a powerful combination drug.
Modified Gila monster venom peptide
Approved July 28, 2016 as Adlyxin
Exendin-4 with 6 extra lysines at the tail
Daltons
Within one hour before first meal
Combined with insulin glargine
Zealand Pharma Scientists
The Peptide Architects · Zealand Pharma, Copenhagen, Denmark
Zealand's chemists took the Gila monster peptide exendin-4 and gave it a makeover. They removed one amino acid (proline) and added six lysine residues to the tail end. This small change made the peptide more stable and gave it a unique profile — especially strong at controlling blood sugar spikes right after meals.
We didn't just want another copy of exendin-4. We wanted a molecule with its own personality — one designed specifically for mealtime control.
Sanofi Development Team
The Global Builders · Sanofi, Paris, France
In 2003, Sanofi licensed lixisenatide from Zealand Pharma and took on the enormous task of global development. They ran the massive GetGoal clinical trial program across dozens of countries and eventually created Soliqua — a groundbreaking combination of lixisenatide with insulin glargine in a single injection.
Combining a GLP-1 drug with insulin in one pen was a dream for years. With Soliqua, we made it real.
Dr. Julio Rosenstock
The Trial Leader · Dallas Diabetes Research Center
Led key ELIXA cardiovascular outcome trials and GetGoal studies that proved lixisenatide was safe for the heart and effective at controlling post-meal blood sugar spikes — its biggest clinical strength.
Lixisenatide showed us that you don't have to be the most powerful drug to be the most useful. Sometimes being best at one thing matters more.
11 milestones, 1992 – 2020.
- 1992John Eng discovers exendin-4 in Gila monster venom — the parent molecule of lixisenatide
- 2001Zealand Pharma begins modifying exendin-4 by adding six lysine residues
- 2003Sanofi licenses lixisenatide from Zealand Pharma for global development
- 2008GetGoal clinical trial program begins across dozens of countries
- 2010ELIXA cardiovascular safety trial begins enrolling over 6,000 patients
- 2013European Medicines Agency approves lixisenatide as Lyxumia
- 2015ELIXA results confirm heart safety but show no cardiovascular benefit
- 2016FDA approves Adlyxin (lixisenatide) on July 28 for type 2 diabetes
- 2016FDA approves Soliqua — lixisenatide combined with insulin glargine
- 2017Soliqua launches commercially, giving patients a single-injection option
- 2020Real-world studies confirm Soliqua benefits in diverse patient populations
Imagine you have a security guard who's especially good at one job: checking IDs at the front door right when guests arrive. Lixisenatide is like that guard — it works best right at mealtimes, slowing down how fast food leaves your stomach and stopping blood sugar spikes right when they happen.
Molecular structure
- Amino Acids
- 44
- Molecular Weight
- 4,858 Da
- Half-life
- ~3 hours
- Based On
- Exendin-4
- Formula
- C₂₁₅H₃₄₇N₆₁O₆₅S
- Key Modification
- 6 extra lysines
Soliqua was groundbreaking
Cardiovascular safety proven
As Lyxumia or Adlyxin
Strongest mealtime GLP-1 effect
Real stories, real lives
Teresa Martinez
My blood sugar was fine in the morning but went crazy after every meal. My doctor put me on Adlyxin before breakfast, and for the first time my after-meal numbers looked normal. I stopped dreading lunch and dinner.
William Johnson
I was taking insulin glargine plus a separate GLP-1 injection — two shots every day. When Soliqua came out and combined them into one pen, my doctor switched me immediately. Same results, half the needles. It sounds simple, but it made a real difference in my daily life.
The future of Lixisenatide
- Fixed-Dose CombinationsApproved
Soliqua (insulin glargine + lixisenatide) continues to serve patients who need both drugs in one injection
- Neuroprotection ResearchPreclinical
Like other GLP-1 drugs, lixisenatide is being studied for potential brain-protective effects
- Improved FormulationsResearch
Longer-acting versions and new delivery methods under investigation
- New Combination PartnersClinical Trials
Testing combinations with newer diabetes drugs for patients who need intensive therapy
Be inspired
The story of Lixisenatide is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.